The Synthesis of Novel GABA Uptake Inhibitors. 1. Elucidation of the Structure-Activity Studies Leading to the Choice of (R)-1-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic Acid (Tiagabine) as an Anticonvulsant Drug Candidate

Journal of Medicinal Chemistry

Volumn 36, Issue 12, 1993, Pages 1716-1725

  Andersen, Knud Erik ^a   Braestrup, Claus ^a   Grønwald, Frederik C ^a   Jørgensen, Anker S ^a   Nielsen, Erik B ^a   Sonnewald, Ursula ^a   Sørensen, Per O ^a   Suzdak, Peter D ^a   Knutsen, Lars J S ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; GUVACINE DERIVATIVE; NIPECOTIC ACID DERIVATIVE; NNC 050328; TIAGABINE; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID UPTAKE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; SYNAPTOSOME;

ANIMAL; ANTICONVULSANTS; COMPARATIVE STUDY; GABA ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; MOLECULAR STRUCTURE; NICOTINIC ACIDS; NIPECOTIC ACIDS; PROSENCEPHALON; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTOSOMES;

EID: 0027241691     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00064a005     Document Type: Article

References (69)

1. De Robertis, E. GABAergic Neurotransmission. An Overview. In GABA and Endocrine Function; Racagni, G., Donoso, A., Eds.; Raven Press: New York, 1987; pp 1–12.
2. Gottlieb, D. I. GABAergic Neurons. Sci. Am. 1988, 38–45.
3. Fonnum, F. Biochemistry, Anatomy, and Pharmacology of GABA Neurons. In Psychopharmacology: The Third Generation of Progress; Melzer, H. Y., Ed.; Raven Press: New York, 1987; pp 173–182.
4. Meldrum, B. S. Epilepsy and Gamma-aminobutyric Acid Mediated Inhibition. Int. Rev. Neurobiol. 1975, 17, 1–36.
5. Löscher, W. GABAmimetics in Animal Models of Seizure States. In Epilepsy and GABA Receptor Agonists Basic and Therapeutic Research (L.E.R.S. Monograph Series Vol. 3); Bartholom, G., Bossi, L., Lloyd, K. G., Morselli, P. L., Eds.; Raven Press: New York, 1985; pp 109–119.
6. Meldrum, B. Mechanism Based Approaches to Anticonvulsant Therapies: Modulation of Inhibitory and Excitatory Transmission. In Current and Future Trends in Anticonvulsant, Anxiety, and Stroke Therapy; Wiley-Liss Inc.: New York, 1990; pp 31–43.
7. Curtis, D. R. GABAergic Transmission in the Mammalian Central Nervous System. In GABA-Neurotransmitters: Pharmacochemical Biochemical and Pharmacological Aspects; Krogsgaard-Larsen, P., Scheel-Krüger, J., Kofoed, H., Eds.; Munksgaard: Copenhagen, 1978; pp 17–27.
8. Enna, S. J. GABA Receptor Pharmacology. Functional Considerations. Biochem. Pharmacol. 1981, 30, 907–913.
9. Krogsgaard-Larsen, P. γ-Aminobutyric Acid Agonists, Antagonists, and Uptake Inhibitors. Design and Therapeutic Aspects. J. Med. Chem. 1981, 24, 1377–1383.
10. Krogsgaard-Larsen, P.; Hjeds, H.; Falch, E.; Joergensen, F. S.; Nielsen, L. Recent Advances in GABA Agonists, Antagonists and Uptake Inhibitors: Structure-Activity Relationships and Therapeutic Potential Adv. Drug. Res. 1988, 17, 381–456.
11. Schechter, P. J. Vigabatrin. In New Anticonvulsant Drugs; Meldrum, B. S., Porter, R. J., Eds.; John Libby: London, 1986; pp 265–275.
12. Lewis, P. J.; Richens, A. Vigabatrin: A New Anti-Epileptic. Br. J. Clin. Pharmacol. 1989, 27 (suppl. 1).
13. Krogsgaard-Larsen, P.; Falch, E.; Larsson, O. M.; Schousboe, A. GABA Uptake Inhibitors; Relevance to Antiepileptic Drug Research. Epilepsy Res. 1987, 1, 77–93.
14. Krogsgaard-Larsen, P. GABA Synaptic Mechanisms: Stereochemical and Conformational Requirements. Med. Res. Rev. 1988, 8, 27–56.
15. Hoehn-Saric, R. Effects of THIP on Chronic Anxiety. Psychopharmacology 1983, 80, 338–341.
16. Yunger, L. M.; Fowler, P. J.; Zarevics, P.; Setler, P. E. Novel Inhibitors of γ-Aminobutyric Acid (GABA) Uptake: Anticonvulsant Actions in Rats and Mice. J. Pharm. Exp. Ther. 1984, 228, 109–115.
17. Löscher, W. Anticonvulsant Action in the Epileptic Gerbil of Novel Inhibitors of GABA Uptake. Eur. J. Pharmacol. 1985, 110, 103–108.
18. Schwark, W. S.; Löscher, W. Comparison of the Anticonvulsant Effects of Two Novel GABA Uptake Inhibitors and Diazepam in Amygdaloid Kindled Rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 1985, 329, 367–371.
19. Silva-Barrat, C.; Brailowsky, S.; Riche, D.; Menini, C. Anticonvulsant Effects of Localized Chronic Infusions of GABA in Cortical and Reticular Structures of Baboons. Exp. Neurol. 1988, 101, 418–427.
20. Krogsgaard-Larsen, P.; Labouta, I. M.; Meldrum, B.; Croucher, M.; Schousboe, A. GABA Uptake Inhibitors as Experimental Tools and Potential Drugs in Epilepsy Research. In Neurotransmitters, Seizures and Epilepsy; Morselli, P., Lloyd, K. G., Löscher, W., Meldrum, B. S., Reynolds, E. H., Eds.; Raven Press: New York, 1981; pp 23–25.
21. Nielsen, L.; Brehm, L.; Krogsgaard-Larsen, P. GABA Agonists and Uptake Inhibitors. Synthesis, Absolute Stereochemistry, and Enantioselectivity of (R)-(−)-and (S)-(+)-Homo-β-proline. J. Med. Chem. 1990, 33, 71–77.
22. Johnston, G. A. R.; Allan, R. D.; Kennedy, S. M. G.; Twitchin, B. Systematic Study of GABA Analogues of Restricted Conformation. In GABA-Neurotransmitters: Pharmacochemical Biochemical and Pharmacological Aspects; Krogsgaard-Larsen, P., Scheel-Kruger, J., Kofoed, H., Eds.; Munksgaard: Copenhagen, 1978; pp 147–164.
23. Myers, R. D. Blood-Brain Barrier: Techniques for the Intracerebral Administration of Drugs. In Handbook of Pharmacology, Vol. II; Iversen, L. L., Iversen, S. D., Snyder, S. H., Eds.; Plenum Press: New York, 1975; pp 1–28.
24. Bodor, N.; Brewster, M. E. Problems of Delivery of Drugs to the Brain. Pharmacol. Ther. 1983, 19, 337–386.
25. Frey, H.-H.; Popp, C.; Löscher, W. Influence of Inhibitors of High Affinity GABA Uptake on Seizure Thresholds in Mice. Neuropharmacology 1979, 18, 581–590.
26. Hinko, C. N.; Crider, A. M.; Wood, J. D. A Comparison of Prodrug Esters of Nipecotic Acid. Neuropharmacology 1988, 27, 475–483.
27. Ali, F. E.; Bondinell, W. E.; Danbridge, P. A.; Frazee, J. S.; Garvey, E.; Girard, G. R.; Kaiser, C.; Ku, T. W.; Lafferty, J. J.; Moonsammy, G. I.; Oh, H.-J.; Rush, J. A.; Setler, P. E.; Stringer, O. D.; Venslavsky, J. W.; Volpe, B. W.; Yunger, L. M.; Zirkle, C. L. Orally Active and, Potent Inhibitors of Gamma Aminobutyric Acid Uptake. J. Med. Chem. 1985, 28, 653–660.
28. Löscher, W.; Schmidt, D. Which Animal Models Should Be Used in the Search for New Antiepileptic Drugs? A Proposal Based on Experimental and Clinical Considerations. Epilepsy Res. 1988, 2, 145–181.
29. Schwark, W.; Haluska, M. Prophylaxis of Amygdala-Kindling Induced Epileptogenesis: Comparison of a GABA Uptake Inhibitor and Diazepam. Epilepsy Res. 1987, 1, 63–69.
30. N'Goka, V.; Schlewer, G.; Linget, J.-M.; Chambon, J.-P.; Wermuth, C.-G. GABA Uptake Inhibitors: Construction of a General Pharmacophore Model and Successful Prediction of a New Representative. J. Med. Chem. 1991, 34, 2547–2557.
31. Pavia, M. R. Preparation and Formulation of N-Substituted 3-Piperidine or 3-Pyridine-carboxylic acid and their Derivatives for the Treatment of Epilepsy. Warner Lambert Company, Eur. Pat. E.P. 221572 (Cl. C07 D211/60), 13 May 1987.
32. Bjorge, S.; Black, A.; Bockbrader, H.; Chang, T.; Gregor, V. E.; Lobbestael, S. J.; Nugiel, D.; Pavia, M. R.; Radulovic, L.; Woolf, T. Synthesis and Metabolic Profile of CI-966: A Potent, Orally-Active Inhibitor of GABA Uptake. Drug Dev. Res. 1990, 21, 189–193.
33. Taylor, C. P.; Vartanian, M. G.; Schwarz, R. D.; Rock, D. M.; Callahan, M. J.; Davis, M. D. Pharmacology of CI-966: A Potent GABA Uptake Inhibitor, In Vitro and in Experimental Animals. Drug Dev. Res. 1990, 21, 195–215.
34. Taylor, C. P. GABA Receptors and GABAergic Synapses as Targets for Drug Development. Drug Dev. Res. 1990, 21, 151–160.
35. Braestrup, C.; Nielsen, E. B.; Wolffbrandt, K. H.; Andersen, K. E.; Knutsen, L. J. S.; Sonnewald, U. Modulation of GABA Receptor Interaction with GABA Uptake Inhibitors. Int. Congr. Ser.-Excerpta Med. 1987, 750 (Pharmacology), 125–128.
36. Nielsen, E. B.; Suzdak, P. D.; Andersen, K. E.; Knutsen, L. J. S.; Sonnewald, U.; Braestrup, C. Characterization of Tiagabine (NO-328), a New Potent and Selective GABA Uptake Inhibitor. Eur. J. Pharmacol. 1991, 196, 257–266.
37. Braestrup, C.; Nielsen, E. B.; Sonnewald, U.; Knutsen, L. J. S.; Andersen, K. E.; Jansen, J. A.; Frederiksen, K.; Andersen, P. H.; Mortensen, A.; Suzdak, P. D. (R)-N-[4,4-Bis(3-Methyl-2-Thienyl)-but-3-en-1-yl] Nipecotic Acid Binds with High Affinity to the Brain γ-Aminobutyric Acid Uptake Carrier. J. Neurochem. 1990, 54, 639–647.
38. Rekling, J. C.; Jahnsen, H.; Mosfeldt Laursen, A. The Effect of Two Lipophilic γ-Aminobutyric Acid Uptake Blockers in CA1 of the Rat Hippocampal Slice. Br. J. Pharmacol. 1990, 99, 103–106.
39. Picardo, A.; Gent, P.; Feely, M. Anticonvulsant Tolerance and Recovery During Repeated Administration of the GABA Uptake Inhibitor NO-328. Br. J. Pharmacol. 1990, 99 (Proc. Suppl. April), Abstract 131P.
40. Sheardown, M. J.; Weis, J. U.; Knutsen, L. J. S.; Swedberg, M. D. B.; Suzdak, P. D. Analgesic Effect of the GABA Uptake Inhibitor NO-328 (N-[4,4-Di(3-methyl-2-thienyl)but-3-en-1-yl)nipecotic Acid. 19th Annual Meeting of the Society for Neuroscience, Phoenix, AZ, U.S.A., October 29–November 3, 1989. Soc. Neurosci. Abstr. 1989, 15, 602.
41. Nielsen, E. B. Anxiolytic effect of NO-328, a GABA Uptake Inhibitor. Psychopharmacology 1988, V96, N1, S42.
42. Judge, M. E.; Swedberg, M. D. B.; Suzdak, P. D. Tolerance to the Cognitive Impairing Effects but not to the Anticonvulsant Effects of NO-328, a Selective GABA Uptake Inhibitor. Eur. J. Pharmacol. 1990, 183, 467.
43. Mengel, H. B.; Pierce, M. W.; Mant, T.; Christensen, M. S.; Gustafson, L. Tiagabine Safety and Tolerance During 2-weeks Multiple Dosing to Healthy Volunteers. Epilepsia 1991, 32 (suppl. 1), 1991.
44. Chadwick, D.; Richens, A.; Duncan, A.; Dam, M.; Gram, L.; Morrow, J.; Mengel, H.; Shu, V.; McKelvy, J. F.; Pierce, M. W. Tiagabine Hydrochloride. Safety and Efficacy as Adjunctive Treatment for Complex Partial Seizures. Epilepsia 1991, 32 (suppl. 3), 1991.
45. Akkerman, A. M.; De Jongh, D. K.; Veldstra, H. Synthetic Oxytocics. I. 3-(Piperidyl-(N)-Methyl)indoles and Related Compounds. Recl. Trav. Chim. Pays-Bos 1951, 70, 899–916.
46. Bettoni, G.; Duranti, E.; Tortorella, V. Absolute Configuration and Optical Purity of 3-Substituted Piperidines. Gazz. Chim. Ital. 1972, 102, 189–195.
47. Julia, M.; Julia, S.; Giegan, R. Terpenes and Related Compounds From Methyl Cyclopropyl Ketone. Bull. Soc. Chim. Fr. 1960, 1072–1079.
48. Balme, G.; Foumet, G.; Gore, J. The Reaction of Trimethylchlorosilane with Alpha-cyclopropanoic Alcohols in the Presence or in the Absence of Lithium Halogenides. Tetrahedron Lett. 1986, 27, 1907–1908.
49. Kellogg, R. M.; Schaap, A. P.; Harper, E. T.; Wynberg, H. Acid-Catalyzed Brominations, Deuterations, Rearrangements, and De-brominations of Thiophenes under Mild Conditions. J. Org. Chem. 1968, 33, 2902–2909.
50. Torabi, H.; Evans, R. L.; Stavely, H. E. The Reformatsky Reaction with Halolactones. I. Reaction with Nonsteroid Carbonyl Compounds. J. Org. Chem. 1969, 34, 3792–3796.
51. Marxer, A. Grignard Reactions with Haloalkylamines. III. Formation of Oxolanes by a New Ring Closure Reaction of 3-Dimethylaminopropylcarbinol. Helv. Chim. Acta 1969, 52, 262–270.
52. McCaustland, D. J.; Chien, P.-L.; Burton, W. H.; Cheng, C. C. A Structural Modification Study of the Antimalarial 2-(p-Chlorophenyl)-2-(4-piperidinyl)tetrahydrofuran. J. Med. Chem. 1974, 17, 993–1000.
53. Nudelman, N. S.; Vitale, A. A. Carbonylation of Aryllithium Agents in the Presence of Alkyl Halides: One-Pot Synthesis of Diarylalkylcarbinols and Derivatives. J. Org. Chem. 1981, 46, 4625–4626.
54. Short, J. H. Substituted Tetrahydrofurans. Abbott Laboratories, U.S. Patent 3,274,218 (Cl.260-347.7) Sept. 20, 1966.
55. Kabalka, G. W.; Vanna, M.; Vanna, R. S.; Srivastava, P. C.; Knapp, F. F. Tosylation of Alcohols. J. Org. Chem. 1986, 51, 2386–2388.
56. Morlacchi, F.; Cardellini, M.; Liberatore, F. Preparation of Unsaturated Heterocyclic Compounds, II. Synthesis of Guvacine. Ann. Chim. 1967, 57, 1456–1461.
57. Guddal, E. Personal communication.
58. Falch, E.; Krogsgaard-Larsen, P. GABA Uptake Inhibitors. Syntheses and Structure-activity Studies on GABA Analogues Containing Diarybutenyl and Diarylmethoxy-alkyl N-substituents. Eur. J. Med. Chem. 1991, 26, 69–78.
59. Sugasawa, S.; Fujiwara, K. Benzhydryl β-Chloroethyl Ether. Organic Syntheses; Wiley: New York, 1963; Collect. Vol. IV, p 72.
60. Gronvald, F. C.; Braestrup, C. N-(Butenyl Substituted) Azaheterocyclic carboxylic acids. U.S. Patent 5,010,090, 1991.
61. Sonnewald, U. Amino Acid Derivatives. U.S. Patent 4,931,450, 1990.
62. 3H]-GABA into Rat Brain Synaptosomes. Acta Pharmacol. Toxicol. 1978, 42, 73–76.
63. Nelson, H.; Mandiyan, S.; Nelson, N. Cloning of the Human Brain GABA Transporter. FEBS Lett. 1990, 269, 181–184.
64. Guastella, J.; Nelson, N.; Nelson, H.; Czyzyk, L.; Keynan, S.; Miedel, M. C.; Davidson, N.; Lester, H. A.; Kanner, B. I. Cloning and Expression of a Rat Brain GABA Transporter. Science 1990, 249, 1303–1306.
65. Bowery, N. G. GABA Transporter Protein Cloned from Rat Brain. Trends Pharmacol. Sci. 1990, 11, 435–437.
66. Kuhar, M. A GABA Transporter cDNA has been Cloned. Trends Neurosci. 1990, 13, 473–474.
67. Hansch, C.; Björkroth, J. P.; Leo, A. Hydrophobicity and Central Nervous System Agents: On the Principle of Minimal Hydrophobicity in Drug Design. J. Pharm. Sci. 1987, 76, 663–687.
68. Still, W. C.; Kahn, M.; Mitra, A. Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution. J. Org. Chem. 1978, 43, 2923–2925.
69. Johnson, W. S.; Petersen, J. W.; Schneider, W. P. Extension of the Modified Stobbe Condensation. Acid-Catalyzed Decomposition of the Products and a Lacto-enoic Tautomerism. J. Am. Chem. Soc. 1947, 69, 74–79.